Preventing premature non-communicable disease mortality necessitates a thorough review
of one of the most important risk factors for stroke, which is atrial fibrillation (AF). The latter …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Cardiovascular diseases (CVDs) caused by thrombotic events are a significant global health
concern, affecting millions of people worldwide. The international normalized ratio (INR) is …

Abstract Introduction The POPular Genetics trial demonstrated that a CYP2C19 genotype-
guided P2Y 12 inhibitor strategy reduced bleeding rates compared with standard treatment …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Background: Big data and real-world data (RWD) have been increasingly used to measure
the effectiveness and costs in cost-effectiveness analysis (CEA). However, the …

Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …

Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …

Abstract Objective The POPular AGE trial showed that clopidogrel significantly reduced
bleeding risk compared with ticagrelor without any signs of an increase in thrombotic events …